Phil Deschamps, GSW Worldwide
An ideal partner is one that will work with manufacturers on a variable cost basis, providing the ability to scale resources up and down as new products are introduced and marketing and sales needs change.
Agency consolidation has been a popular strategy for large pharma over the past several years. While consolidation has resulted in cost reductions by driving volume into fewer partners, it also redefines marketing as a cost to manage rather than an investment to drive results. As a result of this commoditization, the quality and effectiveness of marketing programs can sometimes suffer.
Phil Deschamps
In the emerging global markets, pharmaceutical manufacturers need to be less focused on consolidation, and more focused on deploying the right resources at the right time, at the right cost, to take advantage of local opportunities.
Although the emerging markets are all growing rapidly, there are substantial differences among these markets that require manufacturers to take very different approaches to achieve commercial success. For example, in some markets companies may need to focus on managing regulatory and access issues, while other markets may require robust sales forces. Traditional advertising agency networks are not particularly well suited to address all of these needs. Instead, manufacturers should be seeking partners with a more diverse set of capabilities that can support a broader range of needs, while increasing flexibility and reducing risk. In addition, because pharmaceutical manufacturers face greater cost pressures and narrower margins in emerging markets, they need to be targeted in their investments.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
